Ocugen, Inc. (OCGN)
Nasdaq · Healthcare · Biotechnology
$1.04+1.96%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $353M
- 52-week range
- $0.97 – $2.73
- 52-week change
- −42.05%
- EPS (trailing)
- −$0.26
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $4.4M (+8.83%)
- Net income
- −$68.0M
- Operating margin
- −1425.7%
- Free cash flow
- −$57.1M
From the company’s annual report on SEC EDGAR.
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Headquarters: Malvern, United States · 116 employees · ocugen.com